New Targeted Drug sac-TMT Improves Survival in Advanced Endometrial Cancer
About this episode
This episode discusses the promising results of the new targeted drug sac-TMT for advanced endometrial cancer.
A new targeted cancer drug called sac-TMT is showing promising results for patients with advanced or recurrent endometrial cancer. In a major Phase 3 clinical trial, the treatment improved both overall survival and progression-free survival compared with standard chemotherapy after previous treatments stopped working. In this episode, we break down the latest TroFuse-005 trial results, how antibody-drug conjugates work, and why this development could change future treatment options for advanc...
More episodes of The Onco Life Podcast
- Personalized Cancer Vaccine Shows Long-Term Promise for High-Risk Melanoma Patients
- Where to Get Uterine Cancer Treatment in Malaysia: What Patients Should Know
- Biotin Supplements May Interfere With Cancer Test Results: What Patients Need to Know
- Blood Test Could Help Predict Breast Cancer Immunotherapy Success With Liquid Biopsy Research
- What Happens if Cervical Cancer Treatment Fails or the Cancer Returns?
- The Role of an Oncologist in Cancer Survivorship Care: Long-Term Support After Treatment
Explore listener stats, chart rankings, contacts and more on the The Onco Life Podcast podcast page.